PALM SPRINGS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. , the world leader in serving science, is showcasing a broad spectrum of laboratory automation capabilities, spanning bench-top solutions to fully integrated platforms, at LabAutomation 2007. These new technologies are designed to further improve workflow efficiency and data reproducibility in two key areas of lab automation and drug discovery research -- cell growth and analysis, and protein crystallization.
"As customers continue to automate their work environment, we are providing them with complete application-based technologies with an emphasis on integrated workflows," said Marc N. Casper, executive vice president of Thermo Fisher Scientific. "Today, we are more capable than ever of improving and optimizing workflows for customers, with automation and robotics solutions resulting from our larger portfolio of technologies and platforms. By combining the latest instrumentation, robotics and software, we can help our customers improve workflow efficiency and maximize data acquisition and management."
At LabAutomation 2007, the company will highlight: - Thermo Scientific Cell Growth and Discovery (CGD) WorkCell(TM): Featuring the Cellomics ArrayScan imager, this automated cell culture solution is the first preconfigured system to offer image analysis technology. It is designed for high-capacity cell growth, supply and in-line image analysis. - Thermo Scientific MaX WorkCell(TM): The MaX WorkCell incorporates best- in-class instrumentation to automate all plate preparation steps, including screen making, drop setting and plate sealing. As part of the Thermo Scientific Rhombix(TM) protein crystallization product series, the MaX WorkCell is the only all-inclusive plate preparation system available to customers today.
On display will be a number of additional technologies from Thermo Fisher Scientific, most notably, the Thermo Scientific Matrix PlateMate automated liquid-handler. This system can be easily integrated into other robotic systems, including the Thermo Scientific CataLyst Express robot.
In addition, Frost & Sullivan has awarded Thermo Fisher Scientific the "2006 Product Line Strategy Award" for its outstanding contribution to the European laboratory automation market. The award acknowledges the distinctive expertise of Thermo Fisher Scientific in advanced laboratory automation solutions, its great insight into customer needs and its market-leading ability to meet the ever-changing demands in drug discovery. With a comprehensive range of technologies aimed at increasing workflow and data management efficiency, Frost & Sullivan distinguishes Thermo Fisher Scientific as a complete solutions provider.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual sales of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include those discussed in Thermo Electron and Fisher Scientific's Quarterly Reports on Form 10-Q for the third quarter of 2006 under the caption "Risk Factors," both of which are on file with the Securities and Exchange Commission and available in the "Investors" section of our Website under the heading "SEC Filings." We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; dependence on customers that operate in cyclical industries; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; exposure to product liability claims in excess of insurance coverage; and the effect of exchange rate fluctuations on international operations. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Media Contact Information: Lori Gorski Phone: 781-622-1242 E-mail: lori.gorski@thermofisher.com Website: www.thermofisher.com Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermofisher.com
Thermo Fisher Scientific Inc.CONTACT: Media, Lori Gorski, +1-781-622-1242, orlori.gorski@thermofisher.com, or Investors, Ken Apicerno, +1-781-622-1294,or ken.apicerno@thermofisher.com, both of Thermo Fisher Scientific Inc.
Web site: http://www.thermofisher.com//
Company News On-Call: http://www.prnewswire.com/comp/877850.html/
